Clinical Trials | December 22, 2025
Ipsen’s FALKON trial falls short in rare FOP study, offers key insights
FOP is a rare genetic disorder caused by mutations in the ALK2 kinase
FOP is a rare genetic disorder caused by mutations in the ALK2 kinase
Xeureka will receive an upfront payment from UBE and will be eligible for milestone payments tied to future research progress
The company also reported significant progress toward its internally defined Sustainable Development Goals
The MAR-Autism Test represents more than 20 years of research at the UC Davis MIND Institute by Judy Van de Water
Using a combination of blood and faecal samples, the service examines key biomarkers, including hereditary genetic status
Emcure becomes the first Indian company to exclusively distribute and commercialise Poviztra, a second brand of Novo Nordisk’s Semaglutide injection for weight management
The additional production will raise the installed capacity by 400 million and available capacity by 240 million at the facility
The company along with its subsidiaries has overall bed capacity of 8800+ beds as on 30th September, 2025
Additional investments planned to expand the site’s capacity and capabilities to support growing manufacturing programs
The announcement came during the inauguration of the college’s Innovation & Incubation Centre and Health Club
Subscribe To Our Newsletter & Stay Updated
